Overall, we report data showing anti-tumor role for miR-100 in GBM, and reveal that regulation of miR-100 levels, plus SMRT/NCOR2 and associated downstream pathways (e.g. HDAC3) are potential therapeutic targets for GBM. This evidence concerns the gene NCOR2 and glioblastoma.